echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > East China Pharmaceuticals has signed an exclusive clinical development and commercialization agreement for ovarian cancer drugs with ImmunoGen, Inc. of the United States

    East China Pharmaceuticals has signed an exclusive clinical development and commercialization agreement for ovarian cancer drugs with ImmunoGen, Inc. of the United States

    • Last Update: 2020-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On October 20, East China Pharmaceuticals announced that its wholly-owned subsidiary, China East China, had reached an exclusive clinical development and commercialization agreement with ImmunoGen, Inc. of the United States.
    East China Pharmaceuticals has acquired the exclusive clinical development and commercialization interest in Greater China for ImmunoGen U.S. Clinical Phase III research product Mirvetuximab Soravtansine (new antibody-coupled drug ADC for the treatment of ovarian cancer).
    east China will pay ImmunoGen a down payment of $40 million and a milestone payment of up to $265 million, as well as an agreed percentage of sales fees.
    announcement, ImmunoGen was founded in 1981 and is registered in Waltham, Massachusetts, USA, and listed on the NASDAQ Stock Exchange in November 1989 under the symbol IMGN, which is currently valued at approximately $1,004 million (october 16, 2020).
    the company uses antibody-drug association technology (ADC) to develop anti-tumor drugs, is one of the world's best-known ADC drug development companies, with a number of innovative products in the development stage.
    2019 total assets of $235 million, net assets -76.12 million, 2019 operating income of $34.78 million, net profit of $104 million.
    since its inception, ImmunoGen has worked in the biopharmaceutical industry with a number of internationally renowned pharmaceutical companies, including Roche, Bayer, Novarma and Sanofi.
    ADC product Kadcyla® (ado-trastuzumab emtansine, Chinese: Hessele, for the treatment of HER2-positive breast cancer) was approved in 2013 and sold by Roche and is currently the world's best-selling ADC product.
    Isatuximab, developed by ImmunoGen, is the world's second CD38 single-resistant treatment for multiple myeloma, approved in the United States in 2020 and sold by Sanofi®.
    Mirvetuximab Soravtansine ("MIRV") adaptation: ovarian cancer (in the study of the first ovarian cancer adaptation: highly expressed platinum-resistant ovarian cancer, including ovarian epithelial cancer, fallopian tube cancer or primary peritonal cancer).
    of action: folic acid lipolyst α (FR alpha) is expressed high in solid tumors such as ovarian cancer, lung cancer and breast cancer, and very low in normal cells.
    MIRV enters tumor cells through internal swallowing effects by binding to FR alpha on the surface of the tumor cell membrane, releases the antimicrothroid drug DM4 under the action of tumor intracellular enzymes, and causes cell cycle abortation and apoptosis by inhibiting micro-tube protein polymerization and micro-tube aggregation.
    currently in the research phase: MIRV is conducting Phase III clinical trials in the United States and has not yet started clinical trials in China.
    East China Pharmaceuticals said that in the future will increase the layout of ADC anti-tumor field, based on unsolveed clinical needs, continuous research and development of ADC products for different types of cancer, relying on the company's existing biotechnology research and development platform and cooperation with the world's leading research and development companies such as ImmunoGen, to strengthen the deep product innovation chain and industrial ecological chain, and ultimately achieve the international layout of East China Pharmaceutical anti-tumor field.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.